Remove Coronary Artery Disease Remove Diabetes Remove Plaque
article thumbnail

Pericoronary adipose tissue attenuation predicts compositional plaque changes: a 12-month longitudinal study in individuals with type 2 diabetes without symptoms or known coronary artery disease

Cardiovascular Diabetology

Pericoronary adipose tissue attenuation (PCATa), derived from coronary computed tomography angiography (CCTA), is a novel marker of inflammation in the coronary arteries. Patients with type 2 diabetes mellitus.

article thumbnail

Safety and possible anti-inflammatory effect of paclitaxel associated with LDL-like nanoparticles (LDE) in patients with chronic coronary artery disease: a double-blind, placebo-controlled pilot study

Frontiers in Cardiovascular Medicine

We investigated whether treatment with LDE-paclitaxel changes plaque progression by coronary CT angiography and is safe in patients with chronic coronary artery disease. Analysis of inflammatory biomarkers and coronary CTA was also performed at baseline and 4 weeks after treatment.

article thumbnail

At What Age Should You Think About Assessing Your Risk For Heart Disease?

Dr. Paddy Barrett

Everyone starts with no plaque in the coronary arteries, but over a long enough time frame, everyone develops plaque in their coronary arteries. By age 80, almost everyone will have evidence of advanced plaque in their coronary arteries, as defined by a cardiac CT 1.

article thumbnail

Relationship between peri-coronary inflammation and coronary vascular function in patients with suspected coronary artery disease

Frontiers in Cardiovascular Medicine

Background In this study, we aim to investigate the relationship between the attenuation of peri-coronary adipose tissue (PCAT) in patients with suspected coronary artery disease (CAD) and the assessment of coronary vascular functions using coronary flow reserve (CFR). HU vs. −81.8 HU;

article thumbnail

7 Things You Can Do To Reduce Your Risk Even If You Already Have Heart Disease.

Dr. Paddy Barrett

A common feedback I get is that people with existing coronary artery disease feel like it doesn’t apply to them. Arguably, applying the principles of prevention offers more bang for buck in the short term for people WITH coronary artery disease than those without coronary artery disease.

article thumbnail

Suboptimal Control of Small Dense Low‐Density Lipoprotein Cholesterol Is Associated With Coronary Plaque Progression: An Intravascular Ultrasound Study

Journal of the American Heart Association

BackgroundPlaque progression (PP) is critical between subclinical atherosclerosis and plaque rupture. P=0.006), especially in diabetic patients (Pearsonr=0.58,P<0.001). Journal of the American Heart Association, Ahead of Print. P<0.001).

article thumbnail

Boston Scientific Receives FDA Approval for the AGENT Drug-Coated Balloon

DAIC

Food and Drug Administration ( FDA ) approval for the AGENT Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.

Stents 105